#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2472	16S	1529	1529	99.93	16S.l15.c30.ctg.1	3076	165.0	0	.	n	.	0	C207T	SNP	207	207	C	863	863	T	280	T,C	104,96	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2472	16S	1529	1529	99.93	16S.l15.c30.ctg.1	3076	165.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1840	1840	C	259	C,G	181,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4800	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4330	228.1	0	.	n	.	0	T695C	SNP	695	695	T	1434	1434	C	357	C	250	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4800	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4330	228.1	0	.	n	.	0	A1638G	SNP	1638	1638	A	2377	2377	G	269	G	196	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4800	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4330	228.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2710	2710	C	286	C	209	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4800	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4330	228.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2784	2784	A	310	A	222	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4800	23S	2890	2890	99.9	23S.l6.c30.ctg.1	4330	228.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3336	3336	C	308	C	231	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	396	folP	855	855	100.0	folP.l6.c4.ctg.1	1909	44.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1265	1267	AGC	59;63;61	A;G;C	41;43;42	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	878	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3693	48.4	1	SNP	p	S91F	1	.	.	271	273	TTC	725	727	TTC	52;52;52	T;T;C	37;36;38	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	878	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3693	48.4	1	SNP	p	G95N	0	.	.	283	285	GGC	737	739	GGC	61;61;61	G;G;C	42;43;42	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	878	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3693	48.4	1	SNP	p	D95G	1	.	.	283	285	GGC	737	739	GGC	61;61;61	G;G;C	42;43;42	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	238	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1512	34.3	1	SNP	p	G45D	0	.	.	133	135	GGC	665	667	GGC	63;63;63	G;G;C	43;42;42	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	202	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1229	32.1	0	.	n	.	0	A197.	DEL	197	197	A	831	831	A	102	A	69	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	794	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3211	50.7	1	SNP	p	D86N	0	.	.	256	258	GAC	678	680	GAC	70;70;76	G;A;C	48;46;51	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	794	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3211	50.7	1	SNP	p	R87W	0	.	.	259	261	CGT	681	683	CGT	76;74;75	C;G;T	54;49;50	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	794	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3211	50.7	1	SNP	p	R87I	0	.	.	259	261	CGT	681	683	CGT	76;74;75	C;G;T	54;49;50	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	794	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3211	50.7	1	SNP	p	S87R	1	.	.	259	261	CGT	681	683	CGT	76;74;75	C;G;T	54;49;50	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	794	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3211	50.7	1	SNP	p	S88P	0	.	.	262	264	TCC	684	686	TCC	75;77;75	T;C;C	49;55;53	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	712	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3009	48.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1729	1731	GGC	60;60;60	G;G;C	42;41;40	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1555	1557	GCC	73;74;74	G;C;C	51;51;51	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1558	1560	ATG	74;76;76	A;T;G	51;52;52	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1570	1572	ACC	77;77;77	A,G;C,A;C	52,1;52,1;53	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1570	1572	ACC	77;77;77	A,G;C,A;C	52,1;52,1;53	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	2071	2073	ACC	50;50;49	A,T;C,A;C	37,1;38,1;38	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2125	2127	GCG	54;53;53	G;C;G	40;38;40	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2125	2127	GCG	54;53;53	G;C;G	40;38;40	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2248	2250	GGT	47;47;47	G;G;T,G	34;34;33,1	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2257	2259	AGC	44;44;43	A;G;C	25;28;27	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	594	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2767	44.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2275	2277	CCG	41;41;41	C,G;C,G;G	28,1;26,1;29	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1002	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3485	56.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1818	1820	CCG	40;40;40	C,G;C;G	27,1;29;25	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	286	porA	1146	1146	99.91	porA.l6.c30.ctg.1	2125	28.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	690	690	C	27	C	16	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	386	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2010	39.0	0	.	p	.	0	Y211_A212insD	INS	631	631	T	1035	1035	T	72	T	49	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	386	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2010	39.0	1	SNP	p	G120K	1	.	.	358	360	AAG	762	764	AAG	57;57;56	A,C;A;G	43,1;44;43	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	386	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2010	39.0	1	SNP	p	A121N	1	.	.	361	363	AAC	765	767	AAC	58;58;58	A;A;C,A	43;43;42,1	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	386	porB1b	1038	1038	99.71	porB1b.l15.c4.ctg.1	2010	39.0	1	SNP	p	N121D	0	.	.	361	363	AAC	765	767	AAC	58;58;58	A;A;C,A	43;43;42,1	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1230	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5197	48.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	138	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1378	21.3	1	SNP	p	V57M	1	.	.	169	171	ATG	680	682	ATG	47;45;45	A;T;G	31;32;32	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
